Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.185 USD | +1.16% | +3.57% | -27.26% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 1,630 | 724.8 | 306.1 | 459 | 340 | 409.2 | - | - |
Enterprise Value (EV) 1 | 1,561 | 775.8 | 612.5 | 837.8 | 257.8 | 186.2 | 67.23 | 409.2 |
P/E ratio | -16.6 x | -4.97 x | -0.54 x | -1.77 x | -1.47 x | -38.4 x | 10.9 x | 2.15 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 11 x | 3.19 x | 3.9 x | 6.08 x | 2.92 x | 1.27 x | 0.97 x | 0.64 x |
EV / Revenue | 10.5 x | 3.41 x | 7.81 x | 11.1 x | 2.22 x | 0.58 x | 0.16 x | 0.64 x |
EV / EBITDA | -16.8 x | -6.42 x | -2.71 x | -4.68 x | -1.66 x | 2.38 x | 0.38 x | 1.31 x |
EV / FCF | -21.9 x | -9.02 x | -2.32 x | -4.79 x | -1.9 x | 1.5 x | 0.39 x | - |
FCF Yield | -4.57% | -11.1% | -43.1% | -20.9% | -52.6% | 66.6% | 257% | - |
Price to Book | 82.1 x | -7.01 x | -1.6 x | -1.28 x | -0.68 x | -1.02 x | -1.19 x | -1.35 x |
Nbr of stocks (in thousands) | 27,327 | 27,877 | 61,220 | 73,684 | 113,718 | 189,460 | - | - |
Reference price 2 | 59.63 | 26.00 | 5.000 | 6.230 | 2.990 | 2.160 | 2.160 | 2.160 |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 148.4 | 227.5 | 78.45 | 75.48 | 116.3 | 323.5 | 420.1 | 639 |
EBITDA 1 | -92.78 | -120.8 | -226.1 | -179 | -155.4 | 78.16 | 174.9 | 313.6 |
EBIT 1 | -93.1 | -121.4 | -226.7 | -179.5 | -155.6 | 43 | 117.8 | 265.9 |
Operating Margin | -62.75% | -53.35% | -289.02% | -237.83% | -133.72% | 13.29% | 28.03% | 41.61% |
Earnings before Tax (EBT) 1 | -97.16 | -143.6 | -269.1 | -233.7 | -209.2 | -10.4 | 90.3 | 339.4 |
Net income 1 | -97.16 | -143.6 | -269.1 | -233.7 | -209.2 | -9.837 | 49.31 | 232.5 |
Net margin | -65.49% | -63.09% | -343.04% | -309.58% | -179.87% | -3.04% | 11.74% | 36.39% |
EPS 2 | -3.590 | -5.230 | -9.310 | -3.520 | -2.030 | -0.0563 | 0.1988 | 1.007 |
Free Cash Flow 1 | -71.29 | -86.05 | -263.8 | -174.8 | -135.5 | 124 | 173 | - |
FCF margin | -48.05% | -37.81% | -336.29% | -231.64% | -116.46% | 38.33% | 41.18% | - |
FCF Conversion (EBITDA) | - | - | - | - | - | 158.65% | 98.89% | - |
FCF Conversion (Net income) | - | - | - | - | - | - | 350.83% | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 15.4 | 18.84 | 18.84 | 18.98 | 18.82 | 24.33 | 25.79 | 50.12 | 33.97 | 32.25 | 137.7 | 46.79 | 67.53 | 71.77 | 78 | 86.3 |
EBITDA 1 | -55.48 | -42.84 | -52.23 | -41.52 | -42.42 | -48.52 | -37.01 | - | -27.51 | -42.36 | 72.27 | -15.23 | -2.046 | 23.2 | - | - |
EBIT 1 | -55.63 | -42.99 | -52.38 | -41.62 | -42.51 | -48.6 | -37.06 | - | -27.53 | -42.37 | 72.27 | -20.71 | -1.94 | -11.32 | 7.1 | 13 |
Operating Margin | -361.2% | -228.23% | -277.99% | -219.3% | -225.92% | -199.78% | -143.71% | - | -81.05% | -131.37% | 52.47% | -44.25% | -2.87% | -15.77% | 9.1% | 15.06% |
Earnings before Tax (EBT) 1 | -65.12 | -56.73 | -66.32 | -55.12 | -55.49 | -61.72 | -49.94 | - | -41.25 | -56.34 | 61.02 | -40.81 | -11.65 | -16.39 | -6.9 | -1.1 |
Net income 1 | -65.12 | -56.73 | -66.32 | -55.12 | -55.49 | -61.72 | -49.94 | - | -41.25 | -56.34 | 61.02 | -34.67 | -15.68 | -17.95 | -6.9 | -1.1 |
Net margin | -422.82% | -301.18% | -352.02% | -290.4% | -294.86% | -253.68% | -193.65% | - | -121.43% | -174.71% | 44.3% | -74.1% | -23.22% | -25.01% | -8.85% | -1.27% |
EPS 2 | -1.770 | -0.9300 | -1.050 | -0.8100 | -0.7600 | -0.7900 | -0.4600 | - | -0.3700 | -0.5000 | 0.3400 | -0.1874 | -0.0874 | -0.0982 | -0.0400 | -0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/22/22 | 5/3/22 | 8/2/22 | 11/1/22 | 2/21/23 | 5/9/23 | 8/1/23 | 8/1/23 | 11/7/23 | 2/27/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | 51 | 306 | 379 | - | - | - | - |
Net Cash position 1 | 68.2 | - | - | - | 82.2 | 223 | 342 | - |
Leverage (Debt/EBITDA) | - | -0.4221 x | -1.355 x | -2.116 x | - | - | - | - |
Free Cash Flow 1 | -71.3 | -86 | -264 | -175 | -135 | 124 | 173 | - |
ROE (net income / shareholders' equity) | -196% | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | -54.3% | -50.6% | -73.2% | -74.2% | -92.2% | -11.6% | 4.75% | 4.22% |
Assets 1 | 178.9 | 283.9 | 367.4 | 314.8 | 226.9 | 84.59 | 1,038 | 5,504 |
Book Value Per Share 2 | 0.7300 | -3.710 | -3.130 | -4.880 | -4.410 | -2.110 | -1.820 | -1.600 |
Cash Flow per Share 2 | - | -3.100 | -9.130 | -2.630 | -1.310 | 0.3600 | -0.1000 | - |
Capex | 0.95 | 0.87 | - | - | - | - | - | - |
Capex / Sales | 0.64% | 0.38% | - | - | - | - | - | - |
Announcement Date | 2/27/20 | 2/23/21 | 2/22/22 | 2/21/23 | 2/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.76% | 409M | |
+40.73% | 739B | |
+31.66% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.66% | 240B | |
+9.43% | 210B | |
-4.99% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- ESPR Stock
- Financials Esperion Therapeutics, Inc.